A team of scientists has been able to halt diabetic condition for six months with the help of insulin-producing cells, bringing the cure for Type 1 diabetes closer to reality.
Experts from US hospitals and institutions including Harvard University managed to transplant cells into mice, which immediately began producing insulin.
The team was also able to show they could prevent the cells being rendered useless by the body's own immune system, which was effectively switched off.
Scientists are now working to replicate the results in people with the condition.
Doug Melton, who led that breakthrough, generated the human islet cells used for the new research from human stem cells developed by him.
Senior author Daniel Anderson said that they are excited by these results and are working hard to advance this technology to the clinic.
Sarah Johnson, UK director of policy and communication at JDRF, said if this study can be replicated in humans then one day we could potentially free people with Type 1 diabetes from a life of insulin injections.
The findings are published in the journals Nature Medicine and Nature Biotechnology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
